Brookhaven Lab's world-class medical-imaging scientists will benefit from collaboration with the highly regarded medical school where research professionals can help identify new molecular targets for radiotracer development and provide access to a broad base of research-subject (patient) populations. The agreement also establishes a mechanism for joint appointments for Brookhaven scientists and the mentoring of Mount Sinai graduate students.
Mount Sinai researchers will gain access to Brookhaven's sophisticated imaging tools - including positron emission tomography (PET), high-field magnetic resonance imaging (MRI), micro-PET, and micro-MRI - as well as Brookhaven's expertise in radiotracer chemistry and specialized facilities for the development of new tracer molecules.
This agreement draws on the complimentary strengths of our two institutions," said Fritz Henn, Brookhaven Lab's new Associate Laboratory Director for Life Sciences.
"Our hope is that this center will foster innovations in radiotracer development and imaging techniques that can be translated to improvements in the understanding, diagnosis, and treatment of disease, as well as advances in drug research and development."
Said Dr. Dennis Charney, Dean of Academic and Scientific Affairs for Mount Sinai School of Medicine and Senior Vice President for Health Sci
Contact: Lucia Lee
The Mount Sinai Hospital / Mount Sinai School of Medicine